Electra Therapeutics Inc.

Electra Therapeutics, Inc. (NASDAQ: ETRA - Get Free Report) Director Orbimed Advisors Llc purchased 245,113 shares of the firm's stock in a transaction on Tuesday, November 3rd. The stock was bought at an average price of $7.86 per share, for a total transaction of $1,926,588.18. Following the acquisition, the director owned 5,175,604 shares in the company,

Electra Therapeutics, Inc. (NASDAQ: ETRA - Get Free Report) Director Carl Gordon acquired 245,113 shares of the company's stock in a transaction that occurred on Tuesday, November 3rd. The shares were bought at an average cost of $7.86 per share, for a total transaction of $1,926,588.18. Following the transaction, the director owned 5,175,604 shares of the

Electra Therapeutics, Inc. (NASDAQ: ETRA - Get Free Report) Director Carl Gordon acquired 245,113 shares of the company's stock in a transaction that occurred on Tuesday, November 3rd. The shares were bought at an average cost of $7.86 per share, for a total transaction of $1,926,588.18. Following the transaction, the director owned 5,175,604 shares of the

Electra Therapeutics, Inc. (NASDAQ: ETRA - Get Free Report) Director Orbimed Advisors Llc purchased 245,113 shares of the firm's stock in a transaction on Tuesday, November 3rd. The stock was bought at an average price of $7.86 per share, for a total transaction of $1,926,588.18. Following the acquisition, the director owned 5,175,604 shares in the company,

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc. (NASDAQ: ETRA) a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, today announced that management will present at the Jefferies Global Healthcare Conference in London on Wednesday, November 18, 2026 at 1:00 p.m.

Electra Therapeutics, Inc. (NASDAQ: ETRA - Get Free Report) Director Carl Gordon bought 1,333,333 shares of the company's stock in a transaction that occurred on Monday, September 21st. The stock was purchased at an average price of $15.00 per share, with a total value of $19,999,995.00. Following the transaction, the director directly owned 5,126,891 shares in

Electra Therapeutics, Inc. (NASDAQ: ETRA - Get Free Report) Director Orbimed Advisors Llc bought 1,333,333 shares of the business's stock in a transaction on Monday, September 21st. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $19,999,995.00. Following the transaction, the director directly owned 5,126,891 shares in the

Kinzey Capital Management, based in Singapore, runs discretionary multi-asset portfolios serving private clients, corporates, families and foundations.

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, today announced the pricing of its upsized initial public offering of 23,333,334 shares of common stock at a price to the public of $15.00 per share. The gross proceeds to Electra from the offering, before deducting underwriting discounts and co…

Drug developer Electra Therapeutics is targeting a valuation of up to $977.6 million in ​its U.S. initial public offering, according ‌to a filing on Monday, extending a comeback in biotech listings this year.